Carlyle Group Inc. Reneo Pharmaceuticals, Inc. Transaction History
Carlyle Group Inc.
- $837 Million
- Q2 2024
A detailed history of Carlyle Group Inc. transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Carlyle Group Inc. holds 2,698,957 shares of RPHM stock, worth $4.53 Million. This represents 0.49% of its overall portfolio holdings.
Number of Shares
2,698,957
Previous 2,698,957
-0.0%
Holding current value
$4.53 Million
Previous $4.48 Million
9.04%
% of portfolio
0.49%
Previous 0.33%
Shares
2 transactions
Others Institutions Holding RPHM
# of Institutions
63Shares Held
29.3MCall Options Held
51.7KPut Options Held
0-
Nea Management Company, LLC Timonium, MD4.79MShares$8.04 Million0.68% of portfolio
-
Tang Capital Management LLC San Diego, CA3MShares$5.03 Million0.55% of portfolio
-
Highbridge Capital Management LLC New York, NY2.92MShares$4.9 Million0.94% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.67MShares$4.49 Million2.88% of portfolio
-
River Vest Venture Management LLC St. Louis, MO2.53MShares$4.26 Million63.0% of portfolio
About Reneo Pharmaceuticals, Inc.
- Ticker RPHM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,479,600
- Market Cap $41.1M
- Description
- Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...